IL112236A - Process for minimizing degradation of activated protein c - Google Patents

Process for minimizing degradation of activated protein c

Info

Publication number
IL112236A
IL112236A IL11223695A IL11223695A IL112236A IL 112236 A IL112236 A IL 112236A IL 11223695 A IL11223695 A IL 11223695A IL 11223695 A IL11223695 A IL 11223695A IL 112236 A IL112236 A IL 112236A
Authority
IL
Israel
Prior art keywords
apc
activated protein
minimizing degradation
autodegradation
denaturant
Prior art date
Application number
IL11223695A
Other languages
English (en)
Other versions
IL112236A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22650141&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL112236(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL112236A0 publication Critical patent/IL112236A0/xx
Publication of IL112236A publication Critical patent/IL112236A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL11223695A 1994-01-05 1995-01-03 Process for minimizing degradation of activated protein c IL112236A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17783294A 1994-01-05 1994-01-05

Publications (2)

Publication Number Publication Date
IL112236A0 IL112236A0 (en) 1995-03-30
IL112236A true IL112236A (en) 1999-12-31

Family

ID=22650141

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11223695A IL112236A (en) 1994-01-05 1995-01-03 Process for minimizing degradation of activated protein c

Country Status (29)

Country Link
EP (2) EP1087011A3 (fi)
JP (1) JP3778588B2 (fi)
KR (1) KR950032287A (fi)
CN (1) CN1109891A (fi)
AT (1) ATE201045T1 (fi)
AU (1) AU1003195A (fi)
BR (1) BR9500017A (fi)
CA (1) CA2139468C (fi)
CO (1) CO4600680A1 (fi)
CZ (1) CZ1395A3 (fi)
DE (2) DE10299053I2 (fi)
DK (1) DK0662513T3 (fi)
ES (1) ES2156190T3 (fi)
FI (1) FI115635B (fi)
GR (1) GR3036277T3 (fi)
HU (1) HUT70465A (fi)
IL (1) IL112236A (fi)
LU (2) LU90992I2 (fi)
NL (1) NL300108I2 (fi)
NO (2) NO320157B1 (fi)
NZ (1) NZ270271A (fi)
PE (1) PE43995A1 (fi)
PL (1) PL180703B1 (fi)
PT (1) PT662513E (fi)
RU (1) RU2167936C2 (fi)
SI (1) SI0662513T1 (fi)
UA (1) UA39178C2 (fi)
YU (1) YU295A (fi)
ZA (1) ZA9514B (fi)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9809304B1 (pt) * 1997-04-28 2011-02-08 formulação liofilizada estável, processo para preparação da mesma, bem como forma de dosagem unitária.
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
EP1557463A1 (en) * 1997-04-28 2005-07-27 Eli Lilly & Company Improved methods for processing activated protein C
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
JP2004511428A (ja) 2000-05-24 2004-04-15 イーライ・リリー・アンド・カンパニー 凝固亢進状態を処置するための製剤および方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c

Also Published As

Publication number Publication date
FI950044A (fi) 1995-07-06
RU2167936C2 (ru) 2001-05-27
SI0662513T1 (en) 2001-10-31
PL180703B1 (pl) 2001-03-30
UA39178C2 (uk) 2001-06-15
CA2139468C (en) 2007-08-21
CN1109891A (zh) 1995-10-11
DE10299053I2 (de) 2004-04-01
PT662513E (pt) 2001-08-30
JPH07206704A (ja) 1995-08-08
EP1087011A2 (en) 2001-03-28
NL300108I2 (nl) 2003-06-02
IL112236A0 (en) 1995-03-30
ES2156190T3 (es) 2001-06-16
KR950032287A (ko) 1995-12-20
FI950044A0 (fi) 1995-01-04
FI115635B (fi) 2005-06-15
NL300108I1 (nl) 2003-02-03
PE43995A1 (es) 1995-12-15
NO950018D0 (no) 1995-01-03
NO2006006I1 (no) 2006-05-15
DE10299053I1 (de) 2003-05-22
DE69520844T2 (de) 2001-11-08
NO320157B1 (no) 2005-11-07
GR3036277T3 (en) 2001-10-31
LU90993I2 (fr) 2003-02-18
CO4600680A1 (es) 1998-05-08
JP3778588B2 (ja) 2006-05-24
LU90992I2 (fr) 2003-02-18
CA2139468A1 (en) 1995-07-06
CZ1395A3 (en) 1995-07-12
NO950018L (no) 1995-07-06
ATE201045T1 (de) 2001-05-15
EP0662513B1 (en) 2001-05-09
DK0662513T3 (da) 2001-05-28
HUT70465A (en) 1995-10-30
EP0662513A1 (en) 1995-07-12
NZ270271A (en) 1996-07-26
PL306671A1 (en) 1995-07-10
BR9500017A (pt) 1995-10-03
DE69520844D1 (de) 2001-06-13
RU95100178A (ru) 1997-03-27
HU9500021D0 (en) 1995-03-28
YU295A (sh) 1997-09-30
EP1087011A3 (en) 2002-02-06
AU1003195A (en) 1995-07-13
ZA9514B (en) 1996-07-03

Similar Documents

Publication Publication Date Title
EA199900980A1 (ru) Улучшенные способы приготовления активированного белка с
BR9407047A (pt) Processo para separaçao de uma proteina de uma soluçao aquosa de proteinas
FI955305A (fi) Tekijä VIII:n vähähappinen vesiliuos
DE69432035D1 (de) Saccharinderivate als proteolytische Enzyminhibitoren
NO2006006I1 (no) Aktivert protein C
GR1001480B (el) Ενζυμικά σκευάσματα περιέχοντα παπαϊνη ή χυμο?ρυψίνη και μέ?οδοι μόνιμης ενζυμικής αποτρίχωσης.
AU8919591A (en) Process for reactivating denatured protein
PL332426A1 (en) Method of obtaining an optically active inorganic salt constituting a derivative of phenyl glycine
ES2141258T3 (es) Enzima y su uso en la preparacion de acido (s)-pipecolico.
TH19245A (th) วิธีป้องกันการสลายของโปรตีนซี
Ashworth Structural Studies on Bovine Carbonic Anhydrase Isozymes
TH26735B (th) กระบวนการสำหรับการลดคอนเทนต์ผลพลอยได้ของคาร์เบนเดซิม
SU1823184A1 (ru) Способ получения вещества, обладающего антипротеазным действием

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees